Etodolac (etodolac)
Last reviewed · Source: First Databank (FDB) drug data
Overview
Etodolac is a prototypical nonsteroidal anti-inflammatory agent (NSAIA).
Etodolac, an indole acetic acid derivative, is a prototypical nonsteroidal anti-inflammatory agent (NSAIA).
The American Society of Health-System Pharmacists, Inc. represents that the information provided in the accompanying monograph was formulated with a reasonable standard of care, and in conformity with professional standards in the field. Readers are advised that decisions regarding use of drugs are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and that the information contained in the monograph is provided for informational purposes only. The manufacturer's labeling should be consulted for more detailed information.
The American Society of Health-System Pharmacists, Inc. does not endorse or recommend the use of any drug. The information contained in the monograph is not a substitute for medical care.
Conventional capsules and tablets and extended-release tablets of etodolac are used for anti-inflammatory and analgesic effects in the acute and chronic symptomatic treatment of osteoarthritis and rheumatoid arthritis. Extended-release tablets of etodolac also are used for the symptomatic treatment of juvenile rheumatoid arthritis in pediatric patients 6-16 years of age. Conventional capsules and tablets of etodolac also are used for the relief of pain.
Extended-release tablets of etodolac are not recommended for the management of acute pain. For additional information on the management of osteoarthritis, see Uses: Osteoarthritis, in Celecoxib 28:08.04.08. For additional information on the management of rheumatoid arthritis, see Uses: Rheumatoid Arthritis, in Methotrexate 10:00.
Generic name: etodolac
Pronunciation: (EE-to-DOE-lak)
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Etodolac
Indications
The following indications are listed for Etodolac:
- Osteoarthritis
- Pain
- Rheumatoid Arthritis
Also known as: Arthritis Deformans, Arthrosis Deformans, Degenerative Arthritis, Degenerative Joint Disease, Degenerative Polyarthritis, Hypertrophic Arthritis, Nodose Rheumatism, Osteoarthrosis, Rheumatic Arthritis, Rheumatic Gout.
Dosing
The lowest possible effective dosage and shortest duration of therapy consistent with treatment goals of the patient should be employed. Dosage of etodolac must be carefully adjusted according to individual requirements and response, using the lowest possible effective dosage.
The manufacturers state that safety and efficacy of etodolac conventional capsules and tablets have not been established in children. Safety and efficacy of extended-release tablets of etodolac have not been established in pediatric patients younger than 6 years of age.
The potential benefits and risks of etodolac therapy as well as alternative therapies should be considered prior to initiating etodolac therapy.
Etodolac is administered orally. While the extent of GI absorption of etodolac administered as conventional capsules or tablets does not appear to be affected substantially by concomitant administration with food or antacids, peak concentrations may be reduced by about 50 or 15-20%, respectively; in addition, the time to peak concentration may be delayed substantially by concomitant administration with food but not antacids.
The extent of GI absorption of etodolac administered as extended-release tablets is not affected substantially by concomitant administration with food or antacids; however, peak plasma concentrations are increased by 54% when the extended-release preparation is administered with food and reduced by 15-20% when administered with antacid. Concomitant administration with antacids does not affect time to peak concentrations.
No dosing information is available for this tab.
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
There is no enhanced messaging for this drug.
There are no contraindication contraindications for this drug.
There are no severe contraindications for this drug.
There are no moderate contraindications for this drug.
Adverse reactions
There is no enhanced messaging for this drug.
There are no severe adverse reactions for this drug.
There are no less severe adverse reactions for this drug.
Precautions
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
No ICD codes are available for this drug.
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.